Disruptive Non-Opioid Surgical Analgesic.
Limited opportunity to invest in InSitu Biologics' AnestaGel™, a patented non-opioid pain relief drug based on technology created by scientists at the Cleveland Clinic.
- 22 US Patents Issued.
- 20 Bill market.
- Raised $343k in 7 days since opening to investments on November 29th.
- $4.80 and $4.90/share capacity already filled.
How to invest; Make a reservation from the offering page, you will then receive a private invitation to invest from InSitu Biologics, in the sequence that your reservation was made.
|Valuation After||Max||Min Raise||Min Per Invstr||Price/Share|
|$21,000,000||$1,000,000||$100,000||$50,000||$5.00 - $5.20|
Skydrop™ Smart Sprinkler Controller RegA+Audition(TM); Cloud-based integrated interface that uses real-time, neighborhood-level weather data along with detailed zone settings, to dynamically adjust the duration and frequency of water cycles.
- Reduces water bill on average of 35%
- Proprietary algorithms
- Designed to further control outdoor automation
- Integrates with top Smart Home automation products
With an estimated 100 million people in the U.S. experiencing drought conditions many states, municipalities, and water districts have been tasked to reduce water use. Fixed watering schedules and improper watering techniques are responsible for up to 50% of the landscape water wasted.
Radiant Pain Relief Centres RegA+Audition(TM); Successful Pain Treatment without Needles or Drugs
Safe, Consistently Effective Results
- 91.4% of all patients complete at zero or near in pain score
- Technology tested and proven at: The Mayo Clinic and Johns Hopkins University
- 20% of the world’s population presently suffers from chronic pain
We encourage you to engage with and give suggestions to Audition companies. They are evaluating the cost effectiveness of raising capital from online investors through their RegA+Audition(TM) offerings. What is RegA+Audition(TM)?
Note that Manhattan Street Capital receives payments from companies that raise capital on our website. See our Fees here.
Rod Turner is the founder and CEO of Manhattan Street Capital, the #1 Growth Capital marketplace for mature startups and mid sized companies to raise capital using Regulation A+. Turner has played a key role in building successful companies including Symantec/Norton (SYMC), Ashton Tate, MicroPort, Knowledge Adventure and more. He is an experienced investor who has built a Venture Capital business (Irvine Ventures) and has made angel and mezzanine investments in companies such as Bloom, Amyris (AMRS), Ask Jeeves and eASIC.